- » Aim and Scope
- » Section Policies
- » Publication Frequency
- » Open Access Policy
- » Archiving
- » Publication Fees
- » Indexation
- » Peer-Review
- » Publishing Ethics
- » Disclosure and Conflict of Interest
- » Plagiarism detection
- » DOI assignment
- » Crossmark Policy
- » Preprint and postprint Policy
- » Founder
- » Subscription
- » Data sharing policy
- » Advertising policy
Aim and Scope
The mission of the stuff is to make in the journal “Pediatric Pharmacology” an international authoritative title. Our everyday goal is to create a favourable healthy environment for both famous authors and young researchers to encourage the publication of their clinical research in our journal.
In the journal "Pediatric Pharmacology" you can get acquainted with clinical recommendations based on the principles of evidence-based medicine, and features of the use of drugs and vaccines in children, get comprehensive information on the effects of drugs on the fetus, on pharmaco-economic studies conducted in our country, as well as about the most unresolved problem of pediatric pharmacology - conducting clinical trials, their legal and ethical aspects. In addition, authors, members of the editorial board, readers are given the opportunity to take part in scientific discussions on the pages of the journal based on published materials, as well as to propose their own topic for discussion, presenting the results of their own research that do not agree with generally accepted data.
The editors of the journal accept various articles for consideration, but preference is given to systematic reviews and meta-analyses, original articles and clinical observations. The editorial board of the journal undertakes to cover all modern achievements in medicine: both highly specialized developments and those of global importance for medical science.
The journal is published in paper and electronic versions: full-text articles in Russian with an English summary, which are freely available on the journal's website.
Both domestic and foreign scientists and doctors are invited to publish in the journal.
Section Policies
Open Submissions Open Submissions |
Indexed |
Peer Reviewed |
Publication Frequency
6 times per year, 1 issue every 2 months
Open Access Policy
This journal provides direct open access to its content based on the following principle: free open access to research results contributes to increased global knowledge sharing.
An open access policy is as defined by the Budapest Open Access Initiative (BOAI) and means that articles are made publicly available on the Internet, allowing all users to read, download, copy, distribute, print, search, link to, or scan the full text of those articles. for indexing, transmitting as data for software, or using it for any other lawful purpose without financial, legal or technical barriers other than those inherent in gaining access to the Internet itself.
For more information please refer to the Budapest Declaration (https://www.budapestopenaccessinitiative.org/).
Archiving
- Russian State Library
- National Electronic-Information Consortium
Publication Fees
Publication in the journal is free of charge for all the authors.
The editorial staff doesn't have any processing, submission or printing charges.
Indexation
Articles of "Pediatric Pharmacology" are indexed by several systems.
“Citation index” is a numerical indicator showing the significance of this article; it is calculated according to the subsequent publications referring to this work.
The journal is indexed in the following systems:
- Russian Scientific Citation Index (RSCI) is bibliographical reference database collecting information about the publications of Russian scientists in Russian and foreign scientific periodicals. The RSCI project is under development since 2005 by the "Electronic Scientific Library" (elibrary.ru). More than 3,900 Russian scientific journals have been posted on the Elibrary platform by 2023. Readers receive more than 7 million full-text articles from the library and view more than 22 million abstracts every year.
- Google Scholar is a freely available search engine that indexes the full text of scientific publications of any format and discipline. Google Scholar Index includes most of European and American peer-reviewed online journals from the leading scientific publishers.
- Ulrich's International Periodicals Directory is a database of periodicals (popular and scientific journals) in all topics; it contains descriptions of almost 300 thousand periodicals and more than 200 thousand of them are currently published. It is used by scientific institutions for conducting researches and analysis of periodicals around the world; for reference work; and in the acquisition of the incoming periodicals and serials. There are links to other databases that allow you to view the journals' content.
- VINITI (All-Russian Institute of Scientific and Technical Information of the Russian Academy of Sciences (VINITI RAS)) is the federal database of Russian and foreign publications on natural sciences, exact sciences, and technical sciences. It has been indexed from 1981 to the present day; updated monthly; annual acquisition is about 1 million documents. The database includes 28 thematic fragments consisting of more than 200 sections.
Peer-Review
All scientific articles submitted to the editorial office of the "Pediatric Pharmacology" journal undergo double-blind peer review.
This type of peer review allows keeping identity of both the author and reviewer hidden, thus there is no conflict of interests, judgment, and reviewers’ assessment is completely independent. Reviewers make recommendations to editors who have voting power. Authors have the right to inform the editors who they do not want to see among their reviewers.
- Reviewers of scientific articles are usually permanent members of the editorial board and/or editorial team of the journal, however, other specialists known for their work in particular fields of medicine may also be involved according to the scientific manuscript's topic. The decision on selection of particular reviewer for the article peer review is made by the chief editor, deputy chief editor, scientific editor, editorial manager. The review period is at least 4 weeks and can be extended at the request of the reviewer.
- Each reviewer has the right to refuse to perform the review in case of obvious conflict of interest affecting the perception and interpretation of the manuscript materials. The reviewer gives recommendations on the further actions for every article according to the results of peer review (each reviewer's decision should be justified):
- the article is recommended for publication in its present form;
- the article is recommended for publication after correction of the shortcomings noted by the reviewer;
- the article needs additional peer review by another specialist;
- the article cannot be published in the journal.
- If the review contains recommendations for correcting and revision the article, the editorial board sends the author the text of the review with proposal to take them into account during preparing the new version of the article or to reject them reasonably (partially or completely). The article revision should not take more than 2 months from the moment of sending the e-mail to the authors about the changes. The revised article will receive an additional round of peer review.
- If the authors decline the suggested revisions, they must notify the editorial staff whether in oral or written form of their refusal to publish the article. If the authors do not return the revised version in 3 months from the date of sending the review, the editorial staff removes it from the list even in the absence of any information on refusal from the authors. In such cases authors will be informed about the manuscript withdrawal from registration due to the expiration of the revision deadline.
- If author and reviewers meet insoluble contradictions regarding the manuscript, the editorial board has the right to send the manuscript for additional peer review. Chief editor resolves any conflict situations at editorial board's meeting.
- Authors must prepare articles in accordance with the rules; make sure the material is proofread before sending. Manuscripts where the rules for authors were not taken into account will not be admitted to peer review. Sloppy preparation of an article suggests sloppy research work and drastically reduces the chances of publication.
- The decision on manuscript rejection is made at editorial board meeting according to the reviewers’ recommendations. The article that was not recommended for publication by editorial board decision cannot be accepted for re-review. Editorial staff of the "Pediatrician" publishing house journals do not have the opportunity to publish all the received materials, thus, articles that are not relevant to readers or have no informational value (according to reviewers) can be rejected without consideration. The notice of refusal to publish the article will be sent to the author via e-mail.
- Editorial staff informs the author about article admission for publication (according to editorial board's decision) and indicates its terms.
- Positive review is not sufficient cause to publish the article. The final decision on publication is made by the editorial board. In case of any conflict situations the decision is made by the chief editor.
- Articles that have received positive reviews and been approved by the editorial board are published in the next issues of the journal (generally, within 2-4 months). Editorial staff must notify the authors about it.
Publishing Ethics
This section is based on the materials of the publishing company of scientific and medical literature Elsevier and on the materials of the Committee on Publication Ethics (COPE).
Introduction
The publication in peer reviewed learned journals is not only the variant of simple scientific communication, but it also contributes significantly to the development of the relevant scientific field. Thus, it is crucial to establish standards for the future ethical behavior of all parties involved in publication process, specifically: journal editors, editorial board, reviewers, authors, publishing house and scientific society of the «Pediatric Pharmacology» journal. Our journal programs prepare “clean report” on the development of scientific thought and research. Moreover, we are also aware of the responsibility for the proper presentation of these “reports” especially in terms of the publication’s ethical considerations stated in this document.
- Editors’ responsibilities
1.1. Publication decision
The editor of the scientific journal "Pediatric Pharmacology" is personally and independently responsible for deciding whether to publish the article or not, and frequently in collaboration with the relevant scientific society. The final decision on publication is made by the chief editor.
The decision on publication should be based on the accuracy and scientific significance of the work. The editor is guided by the journal's policy reviewing the article and deciding to publish it. And is constrained by current legal requirements regarding libel, copyright, legitimacy, and plagiarism.
The editor may discuss the article and reviewer's comments with other editors and reviewers if these discussions are legal and justified without using any materials for personal purposes during the decision making on publish.
1.2. Fairness
The editor of the "Pediatric Pharmacology" journal is obliged to evaluate the content of the manuscript regardless of the authors' race, gender, sexual orientation, religious beliefs, ethnic origin, citizenship, or political preferences.
1.3. Confidentiality
The editor of the "Pediatric Pharmacology" journal must enforce confidentiality and does not disclose information (without the need) on the accepted manuscript to third parties (other than other editors, reviewers, publisher, and founder).
1.4. Disclosure and conflicts of interest
This section is based on the WAME guidelines.
Conflicts of interest are conditions under which people coming into conflict or competing interests that can influence editorial decision-making as well as interpretation of the data in the article. Conflicts of interest can be potential or conscious, as well as existing. Objectiveness can be influenced by personal, political, financial, scientific, or religious factors.
Conflicts of interest can cover the following areas:
- Financial: this conflict may occur when any participant of the publication process has received or expects to receive money (or other financial benefits such as patents or shares), gifts or services that may affect the work related to the publication. Examples: study fees, consultations fees, and public speeches fees, etc.
- Personal relationships: this conflict may occur in case of personal relationships with family, friends, competitors, former colleagues.
- Political and religious beliefs: adherence to one religion or political party can influence the result of article consideration when these issues can be analyzed.
- Institutional affiliation: this conflict may occur when one of the publication process participants is directly associated with the organization interested in publishing.
The editorial board of Pediatric Pharmacology journal may ask authors additional questions or request additional information if necessary.
1.4.1. Editors making final decisions regarding manuscripts should forgo any editorial decisions when there is real or potential conflict of interest related to the considered articles. Other editorial staff involved in editorial decisions should inform editors of their current interest (as they may influence editorial decisions) and refuse to make decisions on their own if there is a conflict of interest. Editors should regularly publish reports on potential conflicts of interest related to their activities or anyone from the journal staff. Invited editors should follow the same procedures.
1.4.2. Editorial staff should not use any information obtained from manuscripts processing for personal purposes.
1.4.3. In case of undisclosed conflict of interest in unpublished article, the editorial board of Pediatric Pharmacology journal acts according to the COPE guidelines.
1.4.4. In case of undisclosed conflict of interest in already published article, the editorial board of Pediatric Pharmacology journal acts according to the COPE guidelines.
1.5. Publication supervision
The editor of the "Pediatric Pharmacology" journal is obliged to inform the chief editor about all conflict situations, as well as about any critical errors or accusations of authors or reviewers of publication ethics violation, in manuscripts submitted to the journal, in order to implement all the actions necessary in these cases, such as: amendments, refutations, withdrawals, uncertainties disclosure.
The editor of the "Pediatric Pharmacology" journal participates in the investigation of any ethical violations of processing manuscripts and published articles and uses best endeavors to resolve any conflict as soon as possible. If necessary, the editor of the Pediatric Pharmacology journal interacts with the author's organization to implement deeper investigation.
1.6. Involvement and cooperation in investigations
The editor together with the publisher (or the scientific society) must take adequate retaliatory measures in case of any ethical claims relating to reviewed manuscripts or published materials. Such measures, in general, include interaction with the authors of the manuscript and argumentation of the relevant complaint or requirement, but may also include interaction with relevant organizations and research centers.
- Editorial board responsibilities
2.1. Principles of the editorial board formation
The editorial staff of the "Pediatric Pharmacology" journal is guided by the COPE principles when forming the editorial board/council.
Potential editorial board/council members may be recommended to the chief editor by current editorial board/council members, reviewers, and authors.
Editors wishing to work in the journal as a member of the editorial board/council can submit an application form to the chief editor.
2.2. Editorial board/council member’s responsibilities:
- Publication of 1 article per year to support the journal.
- Peer review of incoming manuscripts within their profile and in case of no external reviewers. Peer review should be performed via the approved "Pediatric Pharmacology" journal Peer Review Policy.
- Reviewers selection for incoming manuscripts upon executive secretary request; control of the reviewing process of incoming manuscripts.
- Decision making about the possibility of manuscript publishing after all rounds of peer review. Decisions are referred to the chief editor who makes the final decision on the publication.
- Inviting authors and reviewers for collaboration with the journal.
2.3. Editorial board/council member may be dismissed from his/her position for the following reasons:
- violation of publication ethics: withholding of the conflict of interests, information, use of his/her status for personal reasons;
- nonfulfillment of assigned duties during the year without reasonable excuse and without consent of the chief editor;
- at the request of the editorial board/council member.
2.4. Editorial board/council members privileges
- articles from the editorial board/council members of the "Pediatric Pharmacology" journal are considered as a priority;
- members of the editorial board/council of the "Pediatric Pharmacology" journal are relieved from any fees on editorial services;
- the editorial board/council member can participate in events organized by the "Pediatric Pharmacology" journal and by the founding organization without payment;
- the editorial board/council member may take the role of guest editor for the special issue of "Pediatric Pharmacology" journal;
- information on the editorial board/council member is posted on the website of the "Pediatric Pharmacology" journal with all the necessary links to databases profiles, affiliates, and any other data.
2.5. Joining the editorial board
The contribution of potential candidates for the role of the editorial board/council member is considered at regular meetings of the editorial board/council. The final decision on the inclusion of potential candidate to the editorial board/council is made by the chief editor.
- Reviewers’ responsibilities
3.1. Impact on reviewer decisions
Peer review helps the editor to make decision on publication, and throughout appropriate interaction with authors it can also help the author to improve the manuscript quality. Peer review plays crucial middle of scientific approach. The publisher shares the point of view that every researcher who wish to contribute to the publication must do substantial work in the manuscript reviewing.
3.2. Promptness
Any selected reviewer who has insufficient skills to review the manuscript or does not have enough time to perform the work quickly should notify the editor of the Pediatric Pharmacology journal and ask for exclusion from the reviewing process of the relevant manuscript.
3.3. Confidentiality
Any manuscript obtained for peer review should be reviewed as confidential document. This work cannot be opened and discussed with any persons who are not authorized by the editor.
3.4. Manuscript requirements and objectivity
The reviewer is obliged to give an objective assessment. Personal criticism of the author is unacceptable. Reviewers should express their opinions clearly and reasonably.
3.5. Acknowledgement of sources
Reviewers should identify significant published works relevant to the manuscript topic and not included in the reference list. Any statement (observation, conclusion, or argument) published previously must have an appropriate bibliographic reference in the manuscript. Moreover, the reviewer has to draw the editor's attention to the substantial similarity or overlap between the processed manuscript and any other published work within the reviewer's scientific competence.
3.6. Disclosure and conflict of interest
3.6.1. Unpublished data obtained from submitted manuscripts cannot be used in personal studies without the written consent from the author. Information or insights from peer review related to potential benefits should be kept confidential and cannot be used for personal benefit.
3.6.2. Reviewers cannot participate in the review of manuscripts if there is any conflict of interest due to competitive, joint, or other interactions and relationships with any of the authors, companies, or other organizations related to the submitted work.
- Duties of the Authors
4.1. Requirements for manuscripts
4.1.1. The authors of the research should provide reliable results of the work done, and an unbiased discussion of the significance of the research. The data underlying the research must be provided accurately. The research should contain sufficient details and references for possible presentation. False or willful erroneous statements are interpreted as unethical behavior and therefore unacceptable.
4.1.2. Reviews and research articles should be accurate and unbiased, and the Editorial Board's point of view should be rendered clearly.
4.2. Data access and storage
The hereby section of the policy has been developed based on the recommendations of COPE regarding data work issues.
Ensuring that the authors have access to the data obtained during the research, substantiating the content of their publications, is welcomed, but not necessary. The author's consent to provide access to research data does not affect the order on publication.
The authors may be required to provide primary data referring to the manuscript for review by the Editors. The authors should be prepared to ensure open access to this type of information (as per ALPSP-STM Statement on Data and Databases), if feasible, and in any case be they should be prepared to save this data for an appropriate period after publication.
4.2.1. Definition of research data
Research data includes any actual materials recorded on any data storage device used in the process of obtaining research results, digital or non-digital. These include tabular data, code, images, audio and video files, documents, charts, processed and/or primary data. This policy applies to research data that may be required to confirm the reliability of research results provided in articles published by the "Pediatric Pharmacology" journal. Research data include information obtained by the authors ("primary data"), as well as data from other sources assessed by the authors while researching ("secondary data").
4.2.2. Defining exceptions
The hereby policy does not apply to research data that are not required to confirm the reliability of the results presented in the published articles.
The information about data that shall be kept confidential can be transferred as follows: anonymized data could be hosted in research data repositories with restricted access. The author may also publish metadata of research data only and/or a description of the access procedure at the request of other scientists.
4.2.3. Data storage
The preferred way of data sharing is using data repositories. If you need help choosing a repository for hosting data, see the list of repositories on the website: https://repositoryfinder.datacite.org /.
4.2.4. Citing of data
The editorial board of the "Pediatric Pharmacology" journal welcomes the provision of access to research data under the free Creative Commons licenses. The editorial board of the "Pediatric Pharmacology" journal does not insist on the mandatory use of free licenses when data are hosted in third-party repositories. The publisher of the "Pediatric Pharmacology" journal does not claim ownership of the research data provided by the author along with the article.
Send your questions concerning the compliance with this policy to the Executive Secretary of the "Pediatric Pharmacology" journal.
4.3. Genuineness and plagiarism
Authors should make sure that a completely original work is presented, and when using the research or statements of other authors, they should provide appropriate bibliographic references or excerpts.
Plagiarism can exist in many forms, from presenting someone else's work as your own to copying or paraphrasing significant parts of someone else's work (without attribution) and to claiming one's own rights to the results of someone else's research. Plagiarism in all its forms constitutes unethical behavior and is unacceptable.
4.4. Multiplicity, redundancy, and simultaneity of publications
In general, an author should not publish a manuscript, mostly addressing the same research, in more than one journal as an original publication. Submitting the same manuscript to more than one journal at the same time is interpreted as unethical behavior and unacceptable.
In general, an author should not submit a previously published article for consideration by another journal.
Publishing a certain type of article (for example, clinical recommendations, translation of articles) in more than one journal is ethical in some cases if certain conditions are followed. Authors and Editors of interested journals must agree to a secondary publication that provides exact the same data and interpretations as in the first published research.
The bibliography of the primary research should also be provided in the second publication. See the detailed information about the acceptable forms of secondary (repeated) publications on the page www.icmje.org .
4.5. Recognition of primary sources
It is mandatory to recognize the contribution of others. Authors should refer to publications that are relevant to the performance of the submitted research. Data obtained privately, for example during a conversation, correspondence, or in the process of discussion with third parties, should not be used or provided without the explicit written consent of the original source. Information obtained from classified sources, such as the evaluation of manuscripts or the grants, should not be used without the express written consent of the Authors of the research related to classified sources.
4.6. Authorship of the publication
4.6.1. The "Pediatric Pharmacology" journal adheres to the following criteria of the authorship (drafted and described in the ICMJE recommendations):
- a significant contribution to the drafting of the concept or planning of scientific research or the receipt, analysis or interpretation of this research; and
- drafting a manuscript or its recension with the introduction of valuable intellectual content; and
- final approval of the published version of the manuscript; and
- Consent to take responsibility for all aspects of the research and ensuring that all issues related to the accuracy and integrity of any part of the work can be properly investigated and resolved.
4.6.2. In addition to being responsible for those parts of the research that the author performed himself, he (she) should be aware of specific parts of the research the other co-authors are responsible.
Moreover, the authors should be confident in the trustworthiness of their co-authors' contributions. All persons designated as authors must meet all four criteria, and all persons meeting these four criteria must be identified as authors.
4.6.3. If a person does not meet all four criteria, he(she) should be mentioned in the “Acknowledgements" section.
4.7. Contributions from authors and non-authors
People who have contributed to the research but do not meet the criteria of authorship may be mentioned in the “Acknowledgements” section, for example: those who supported the research, performed the role of mentor, assisted in data collection, coordinated the research, etc.
In order to determine the contribution correctly, the authors of the "Pediatric Pharmacology" journal can use one of the algorithms recommended by the COPE:
- General Guidelines for Authorship Contributions
- CRediT – Contributor Roles Taxonomy
4.8. Responsibility
The editors of the "Pediatric Pharmacology" journal are responsible for compliance with the standards of authorship and author's contribution.
The authors must provide transparent and accurate information about the authors of the article and the persons who have made a significant contribution to the preparation of the article.
In order to identify correctly the contribution to the preparation of the article, use the following sources:
- https://www.apa.org/science/leadership/students/authorship-determination-scorecard.pdf
- https://www.apa.org/science/leadership/students/authorship-tie-breaker-scorecard.pdf
4.9. Responsibilities of authors in disclosing conflicts of interest
When authors submit a manuscript of any type or format, they are required to disclose all relationships and activities that may affect or be considered to influence their work.
The author is obliged to notify the editor of a real or potential conflict of interest by including information about the conflict of interest in the appropriate section of the article.
If there is no conflict of interest, the author should also report it. An example of the wording: "The author declares that there is no conflict of interest."
- Ethical supervision
The "Pediatric Pharmacology" journal shares COPE's view that publication ethics includes not only ensuring the integrity and reliability of published research, but also ethical behavior in relation to research subjects. This category includes vulnerable groups of the population, laboratory animals, people (if appropriate research is carried out), classified data and business/marketing methods.
If the research involves the use of chemicals, procedures, or the operation of equipment, that may expose a person to any unusual risk, the author should explicitly indicate it in the manuscript.
5.1. Informed consent.
The "Pediatric Pharmacology" journal requires the informed consent/publication consent to be submitted for any clinical trial where an individual or group of individuals can be identified. If animals or humans are supposed to participate in the clinical trial as objects of research, the authors should make sure that the manuscript indicates that all stages of the clinical trial comply with the legislation and regulatory documents of research organizations, and approved by the relevant committees. The manuscript should explicitly state that informed consent has been obtained from all people who have become objects of clinical trial. Ensuring the privacy rights are respected is mandatory.
5.2. Vulnerable populations
5.2.1. Vulnerable populations include (but not limited to) those who are unable to protect their own interests: pregnant women, newborns, children, fetuses in the womb, prisoners, people with disabilities, with delayed (impaired) intellectual health (development), economically disadvantaged, hospitalized patients in serious condition, etc.
5.2.2. Clinical trials across vulnerable populations should only be planned if these groups benefit from it.
One of the concerns is that not all participants in the clinical trial can understand its conditions for objective reasons. If the informed consent cannot be obtained from a subject of the clinical trial directly, this consent must be signed by his legal representative. Clinical trials where children are participating are the subject of special concerns.
5.2.3. The editorial board of the "Pediatric Pharmacology" journal supports COPE's statement on the publication of clinical trials related to vulnerable groups of the population.
The authors of the articles must obtain informed consent for publication and inform the editorial board of the "Pediatric Pharmacology" journal.
5.3. Ethics for clinical trials involving animals
When conducting a clinical trial involving animals, authors must provide information on compliance with institutional and national standards for the use of laboratory animals.
In order to provide more accurate and correct information about the clinical trial involving animals, the editorial board of the "Pediatric Pharmacology" journal recommends using the ARRIVE standards. Application of these standards will improve the quality and reliability of published articles, as well as allow other researchers to reproduce the results.
5.4. Clinical trials involving humans
In a course of its work, the "Pediatric Pharmacology" journal relies on the provisions of the WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects and strives to ensure compliance with ethical standards and rules for data collection for clinical trials involving humans. Before starting the clinical trial, the scientist should read and understand the provisions on informed consent of the Helsinki Declaration and conduct the research in strict adherence to the principles set out below (see the provisions of the Helsinki Declaration 25-32). When presenting the results of the clinical trial involving humans, the authors should indicate whether the procedures performed complied with the ethical standards prescribed in the Helsinki Declaration. If the clinical trial was conducted without consideration of the principles of the Declaration, the authors must justify the chosen approach to conduct the clinical trial and ensure that the ethics committee of the organization where the clinical trial was conducted approved it.
«25. The participation of persons capable to provide the informed consent as subjects of the clinical trial should be voluntary. Although consultation with relatives or leaders of a social group may be appropriate in some cases, no person who is able to provide the informed consent can be included in the study unless they have given their own voluntary consent.
- In a clinical trial involving people capable to provide the informed consent as subjects of the research, each potential subject should receive sufficient information about the goals, methods, sources of funding, any possible conflicts of interest, affiliation to any organizations, expected benefits and potential risks, and inconveniences that may arise as a result of participation in the research, the conditions in force after the end of the clinical trial, as well as any other significant aspects of it. A potential clinical trial subject should be informed of their right to refuse to participate in the clinical trial or withdraw their consent to participate at any time without any adverse consequences for themselves. Special attention should be paid to the specific information needs of each potential entity, as well as the methods used to provide information.
After ensuring that the potential subject understands the information provided to him, a doctor or other person with appropriate qualifications should obtain the subject's voluntary informed consent to participate in the clinical trial, preferably in writing. If the consent cannot be expressed in writing, the verbal consent must be properly completed and duly executed.
All subjects of medical research should be provided with an opportunity to receive information about the general conclusions and results of the trial.
- When obtaining informed consent to participate in a trial, the doctor should exercise special caution in cases where the potential subject is in a position dependent on the doctor or may give consent under pressure. In such cases, informed consent must be obtained by a person who has the appropriate qualifications and is completely independent of this kind of relationship.
- If the potential subject of the trial is a person who is unable to give informed consent, the doctor must obtain the informed consent of his legal representative. Such persons should not be included in trial that do not have a likely benefit for them, except in cases where such research is conducted to improve the provision of medical care to a group of people represented by a potential subject, cannot be replaced by research on persons who are able to give informed consent, and is associated only with minimal risks and inconveniences.
- If a potential subject, recognized as unable to provide the informed consent, is nevertheless able to express his own attitude towards participating in the trial, the doctor must request his opinion in addition to the consent of his legal representative. The disagreement of the potential subject must be considered.
- Clinical trials involving subjects who are physically or mentally unable to give consent, for example, patients who are unconscious, can only be conducted on condition that a physical or mental condition that prevents informed consent is an integral characteristic of the clinical trial group. In such cases, the doctor must request informed consent from a legal representative. If such a representative is not available, and if the patient's inclusion cannot be delayed, the clinical trial may be conducted without obtaining informed consent, provided that the special reasons for including subjects in the clinical trial in a condition that prevents the provision of informed consent are specified in the study protocol, and the conduct of the clinical trial is approved by the ethics committee. The consent of the subject or his legal representative to continue participating in the clinical trial should be obtained as soon as possible.
- The doctor must provide the patient with complete information about the aspects of treatment relate to the ongoing trial. The patient's refusal to participate in the trial or the decision to withdraw from the trial should not affect his (her) relationship with the doctor.
- In clinical trials where biological materials or data that allow to identify the person from whom they were obtained, for example, in the study of materials or data contained in biobanks or similar repositories are used, the doctor must obtain informed consent to receive, store and/or reuse such materials and data. There may be exceptions where obtaining consent for such a trial is impossible or impractical. In such cases, the trial can only be conducted after consideration and approval by the ethics committee."
5.5. Work with classified data
The privacy right of individuals or organizations involved in the trial is of paramount importance and should not be violated without their informed consent. Authors should take all necessary precautions to protect information about the trial subjects. The authors should take measures to minimize any potential physical and psychological harm to the trial subjects, if necessary.
- Post-publication discussions and changes to published articles
6.1. Updates
6.1.1. In some cases, it may be necessary to update an already published article. The editorial board of the "Pediatric Pharmacology" journal supports the practice of making changes to published materials and, if necessary, acts in accordance with the recommendations of COPE.
6.1.2. If the Author finds significant errors or inaccuracies in the publication, the Author must inform the Editor of the "Pediatric Pharmacology" journal and interact with the Editor in order to withdraw the publication as soon as possible or correct errors. If the Editor or Publisher has received information from a third party that the publication contains significant errors, the Author is obliged to withdraw the work or correct the errors as soon as possible.
6.1.3. Any necessary changes are accompanied by a notification after publication, which will always be linked to the original version of the article so that readers can receive information about all necessary changes. The editorial board of the "Pediatric Pharmacology" journal uses the Expression of doubt, Correction or Withdrawal of the article. The purpose of this practice is to ensure the integrity of scientific materials.
All corrections, expressions of doubt and messages about the withdrawal of the article are published.
6.2. What should authors do if they find an error in their article?
The authors may discover a technical or semantic error after the publication of the article. In such case, the authors should inform the editorial board of the "Pediatric Pharmacology" journal as soon as possible, especially in case of errors that may affect the interpretation of the results or cause doubts about the reliability of the information. The author responsible for the correspondence is responsible for reaching agreement in the author's team on further interaction with the editorial board.
If you think that changes need to be made to the published article, please contact us by e-mail pedpharm@spr-journal.ru.
The algorithm to update the article
6.2.1. Correction
Corrections are made to the article if it is necessary to correct an error or add missing information, and this does not affect the integrity and scientific significance of the article.
Corrections can be made, for example, to the caption, information about the financing of the study can be added or information about a conflict of interest can be clarified.
If such changes are made, a separate correction message is published. The general algorithm of actions is as follows:
- correction is being made to the original version of the article;
- The Crossmark entry is being updated;
- in the “Abstract” field of the original version of the article, a description of the change is made;
- A correction message is published, which contains information about the original version of the article, as well as links to it, the names of the authors and a description of the essence of the correction.
Messages about correcting spelling errors, typos, and other minor changes are not published separately. The website reports that corrections have been made to the article (without details).
6.2.2. Withdrawal of the article
The editorial board of the "Pediatric Pharmacology" journal decides on the need to withdraw the article in the following cases:
- when there is clear evidence that the results are unreliable for a number of reasons: serious errors in the calculations, the data is fabricated, manipulations with images are carried out;
- plagiarism was detected in the article;
- The results have already been published previously in other journals, and the author did not justify the need for re-publication and did not warn the editor about it.;
- the article contains materials and data that have not been authorized for use;
- copyrights have been violated or another serious legal problem has arisen (for example, confidentiality has been violated);
- the ethics of conducting the trial has been violated;
- The review process has been compromised;
- the author did not disclose a conflict of interest, which, in the opinion of the editor, could have influenced the decision of the reviewer or the editor to publish the article.
The editorial board of the "Pediatric Pharmacology" journal operates according to the following algorithm, if necessary, retraction of the article:
- conduct an investigation and make sure that the retraction is necessary;
- prepare a retraction message: include in the title the note “Withdrawal of the article” and the title of the article, describe the reason for the retraction, indicate whose initiative it was, provide a link to the article being withdrawn;
- post a retraction message;
- replace the original version of the withdrawn article by noting in the pdf file that the article has been withdrawn;
- report the retraction to the databases;
- transfer information about the withdrawn article to the database of retracted articles.
The editorial board of the "Pediatric Pharmacology" journal works with withdrawn articles according to COPE regulations.
6.2.3. Expression of doubt
The editorial board of the "Pediatric Pharmacology" journal reports the expression of doubt in the following case:
- Serious concerns were expressed about the published article, but the investigation failed to prove anything, or for some reason the investigation will not be conducted or cannot be completed for a long time. At the same time, it is necessary to notify readers about what is happening as soon as possible.
After the investigation is completed, the article may be amended or it may be withdrawn.
6.2.4. Deleting an article
Articles from the "Pediatric Pharmacology" journal are deleted only in extreme cases when it is impossible to follow the protocol of making changes, withdrawing the article or expressing doubts.
The article can be deleted in the following cases:
- if the distribution of the article may pose a serious risk;
- if the article contains content that violates the right to privacy of the trial subject;
- if the article violates the rights;
- if the article is to be deleted by a court decision.
If an article is deleted, all materials are deleted from the journal's website, requests are sent to databases with a request to delete the full text and post a message about the deletion of the article.
6.3. Updates and post-publication discussions of articles
6.3.1. Addition of the published article
The author may need to supplement the article some time after its publication. In this case, the editorial board of the "Pediatric Pharmacology" journal may publish an addendum to the article. Additions to the article are necessarily checked by the editors of the journal and can be sent for review.
When the supplement is published, the file with the original version of the article is updated, and the current issue of the journal additionally contains a notification about the addition of the article, including information about the article, its authors, the essence of the changes made and a link to the article.
6.3.2. Comment on the published article
Comments are short materials expressing an opinion or observation about the published article. Comments are sent to reviewers and authors of the article so that they have the opportunity to prepare a response to the comment.
The authors' comments are also sent to the reviewer. The author of the comment will have the opportunity to reply to the authors again, after the correspondence between the author of the comment and the authors of the article can continue privately.
The decision to publish comments is made by the editor of the "Pediatric Pharmacology" journal. Comments, answers, and replicas are linked to the original version of the article to which they relate.
- Responsibility of the Publishing House
7.1. The publisher must follow the principles and procedures that facilitate the performance of ethical duties by Editors, Reviewers and Authors of the "Pediatric Pharmacology" journal in accordance with these requirements. The publisher of the "Pediatric Pharmacology" journal is responsible for compliance with all modern recommendations and requirements for maintaining the integrity of scientific materials published there.
7.2. The publisher follows the policy of the "Pediatric Pharmacology" journal in terms of receiving compensation for the preparation and publication of manuscripts, as well as making a profit from printing advertisements and reprints. The publisher must be sure that the potential profit from advertising or reprint production has not influenced the Editors' decisions.
7.3. The publishing house should support the Editors of the "Pediatric Pharmacology" journal in reviewing claims to the ethical aspects of published materials and help interact with other journals and/or Publishers if this contributes to the fulfillment of the duties of the Editors.
7.4. The publisher should promote good research practices and implement industry standards in order to improve ethical guidelines, withdrawal procedures, and error correction.
7.5. The publisher does not interfere in editorial processes, however, if necessary and at the request of editors, it can participate in the investigation of violations of publication ethics, as well as send official requests on its behalf to scientific and educational organizations, as well as other publishers.
7.6. The publisher must provide appropriate specialized legal support (opinion or advice) if necessary.
- Responsibility of the Founder
8.1. The founder of the "Pediatric Pharmacology" journal adheres to the principle of editorial independence: the director of the founding organization and its staff do not interfere in the editorial process.
8.2. The founder of the "Pediatric Pharmacology" journal can recommend potential members of the editorial board/editorial board, reviewers and authors, however, the final decision on the possibility of cooperation with them is made by the editor-in-chief only.
8.3. The founder of the "Pediatric Pharmacology" journal supports the need to ensure geographical and gender diversity among the members of the editorial board/editorial Board, reviewers and authors.
8.4. The founder of the "Pediatric Pharmacology" journal does not put financial and political benefits above the quality of the journal. The editors of the "Pediatric Pharmacology" journal decide on the publication of manuscripts based on their quality and interest to the target audience of the journal.
8.5. The founder of the "Pediatric Pharmacology" journal does not interfere in editorial processes, however, if necessary and at the request of the editors, he can participate in the investigation of violations of publication ethics and send official requests on his behalf to scientific and educational organizations, as well as other publishers.
- Complaints and appeals
The editorial board of the "Pediatric Pharmacology" journal pays special attention to complaints about the behavior of editors and reviewers, which may relate to issues such as violation of confidentiality, undisclosed conflicts of interest, misuse of confidential information obtained during the review process. Also, authors may disagree with decisions regarding expressing doubts about certain articles or complain about violations of editorial processes.
All complaints can be sent by e-mail pedpharm@spr-journal.ru. They will be considered routinely. The complaint review process does not take more than 7 days. The person who filed the complaint receives information about the decision, as well as about the measures that will be taken and the timing of their implementation.
While reviewing complaints, the editorial board relies on COPE guidelines in each of the following cases:
- working with post-publication critics
- post-publication discussions and updates
- suspicion of manipulation of the review after publication
- manipulations with images in a published article
- fabrication of data in a published article
Disclosure and Conflict of Interest
Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.
Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.
Plagiarism detection
«Pediatricheskaya farmakologiya» («Pediatric pharmacology») use native russian-language plagiarism detection software Antiplagiat to screen the submissions. If plagiarism is identified, the COPE guidelines on plagiarism will be followed.
Authors who use data from other studies in their work should correctly refer to primary sources, since they are fully responsible for the accuracy of the data given in the list of references. Authors should not copy references to references from other publications unless they have read the referenced works.
It is not allowed to send to the editorial office works that are duplicated in other publications or sent for publication to other editions.
DOI assignment
All articles of the "Pediatrician" publishing house journals (Pediatric Pharmacology, Current Pediatrics, Annals of the RAMS, Russian Pediatric Journal) are automatically assigned with unique DOI number when posted on the website.
DOI, or digital object identifier, is the standard for indicating the information provision on the Internet. It always remains constant, thus, it is easy to identify the author, his article or book.
In short, DOI is a publication address that never changes. In case if you change the object's URL (article, book), it is enough for the publisher to make changes to the database with DOI.
Electronic publishing platforms and databases around the world use it as the standard around the world. It is assumed that electronic publications without DOI number are not correctly uploaded on the Internet and may disappear, and it will negatively affect the citation of authors. Therefore, the DOI assignment is one of the necessary criteria for the abstract inclusion in such databases as Web of Science and Scopus. It is important that due to DOI author's article from any journal can be included in Scopus or Web of Science, if the author of the journal publication included in these databases cites it.
You can find the publication by DOI number on the following websites: International DOI Foundation (IDF) and CrossRef.
Publishing houses that have entered DOI assignment agreement have to:
- timely register DOI for new publications;
- recognize DOI for cited articles and post links to them on the platform via DOI;
- maintain URL-DOI pages with bibliographic information about the object and description of how to obtain the full text.
Crossmark Policy
CrossMark is a multi-publisher initiative from Crossref, provides a standard way for readers to locate the authoritative version of an article or other published content. By applying the CrossMark logo, journal «Pediatricheskaya farmakologiya» («Pediatric pharmacology») is committing to maintaining the content it publishes and to alerting readers to changes if and when they occur.
Clicking the CrossMark logo on a document will tell you its current status and may also give you additional publication-record information about the document.
Preprint and postprint Policy
Prior to acceptance and publication in «Pediatricheskaya farmakologiya» («Pediatric pharmacology»), authors may make their submissions available as preprints on personal or public websites.
As part of submission process, authors are required to confirm that the submission has not been previously published, nor has been submitted. After a manuscript has been published in «Pediatricheskaya farmakologiya» («Pediatric pharmacology») we suggest that the link to the article on journal's website is used when the article is shared on personal or public websites.
Read more here.
Founder
Union of pediatricians of Russia
Unit 4/1, 54–4 Vavilova Street, 119296, Moscow, Russian Federation
Phone number: 8 (499)132-02-03
e-mail: info@pediatr-russia.ru
Subscription
"Pediatrician" publishing house invites you to enter a subscription to the print version of the "Pediatric pharmacology" journal.
You need to register on the Publishing house website, fill out the address information in the your profile and place an order.
Subscription prices for printed versions of journals (excluding delivery in Russian Federation):
1-year subscription (6 issues) | 1500,00 (RUB) |
6-months subscription (3 issues) | 750,00 (RUB) |
One issue | 250,00 (RUB) |
Subscription via agency Ural-Press District LLC. Subscription index — 88005.
Editorial subscription:
- subscription from any issue
- reduced delivery time
- immediate decision of emerging problems
For companies
It is necessary to send subscription request form (journal name and subscription terms) and corporate details via e-mail (sales@spr-journal.ru) to process invoice documents.
Editorial staff address: Unit 4/1, 54–4 Vavilova Street, 119296, Moscow, Russian Federation
Tel: +7 (499) 132-02-07, +7 (916) 650-01-27
Е-mail: sales@spr-journal.ru
Data sharing policy
Authors are encouraged to make the research data that support their publications available but are not required to do so. The decision to publish will not be affected by whether or not authors share their research data.
Definition of research data
This policy applies to the research data that would be required to verify the results of research reported in articles published in the journal «Pediatric pharmacology». Research data include data produced by the authors (“primary data”) and data from other sources that are analysed by authors in their study (“secondary data”). Research data includes any recorded factual material that are used to produce the results in digital and non-digital form. This includes tabular data, code, images, audio, documents, video, maps, raw and/or processed data.
Definition of exceptions
The data that is not a subject to public disclosure may be delivered as follows: deposited in science data repositories with limited access or preliminary anonymised. An author can also publicly deliver metadata only and/or description of the method of access to the data under requests from other scholars.
Data repositories
The preferred mechanism for sharing research data is via data repositories. Please see or https://repositoryfinder.datacite.org/ for help finding research data repositories.
Data citation
The Editorial Board of the Journal «Pediatric pharmacology» welcomes access to data under Creative Commons Licenses. Editorial Board of the Journal «Pediatric pharmacology» does not insist on the obligatory use of Creative Commons in case when the data is deposited in the repositories of the third party. The Publisher of the Journal «Pediatric pharmacology» does not assert any copyrights for the data submitted by the author together with the article.
Questions regarding the observation of that policy shall be sent to the executive secretary of the Journal «Pediatric pharmacology».
Advertising policy
The editors are responsible for the placement of advertising materials within the limits established by the advertising policy of the journal “Pediatric Pharmacology”, located at: https://www.pedpharma.ru/jour/pages/view/advertising_policy
The editors take all measures established by law to publish legal and correct advertising.
